Body weight change associated kidney outcomes of sodium–glucose cotransporter new users
Authors' conclusion
Our analysis of a nationwide epidemiological cohort revealed that kidney outcomes following the initiation of SGLT2 inhibitors would be more favourable, with greater body weight loss observed after the initiation of SGLT2 inhibitors.
Study context
- Population
- Individuals with diabetes newly prescribed SGLT2 inhibitors; median age 52 (Q1-Q3: 47–58) years, median HbA1c 7.4%, median estimated glomerular filtration rate (eGFR) 77.7 mL/min/1.73 m²
- Participants
- 11,569 individuals
- Exposure
- Tertiles of 1-year BMI change rate after SGLT2i initiation
- Outcome
- Rate of decline in eGFR (linear mixed-effects model)
- Follow-up
- Median 1.7 (Q1-Q3: 1.0-2.6) years
Methodological detailsnationwide epidemiological database
- Nationwide epidemiological database
Main finding
As reported in the abstract
Annual change in eGFR
Tertile 1
−0.78
CI −0.94–-0.63 · mL/min/1.73 m²
Tertile 2
−0.95
CI −1.09–-0.81 · mL/min/1.73 m²
Tertile 3
−1.65
CI −1.84–-1.47 · mL/min/1.73 m²
P for interaction < 0.001
Observational data: associations, not effects.
Further findings
- Sensitivity analyses confirmed the relationship between 1-year BMI decrease and favourable kidney outcomes after SGLT2i
Original publication
Body weight change associated kidney outcomes of sodium–glucose cotransporter new users. Diabetes Obes Metab. Published 28 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →